Copyright © 1999 by the European Society of Cardiology.
Differences in drug treatment of chronic heart failure between European countries
a Department of Cardiology/Thoraxcentre, University Hospital Groningen, Groningen
b Academic Medical Centre, Amsterdam, The Netherlands
c Nottingham Clinical Trial Data Centre, Queen’s Medical Centre, University Hospital, Nottingham, U.K.
d Cardiovascular Medicine, Queen’s Medical Centre, University Hospital, Nottingham, U.K.
revised September 22, 1998; accepted September 30, 1998
Abstract
Aims
A large number of drugs are currently used for the treatment of chronic heart failure. Treatment for other cardiovascular disorders has been shown to differ between countries. In this study we examined whether this would also be true in heart failure.
Methods and Results
We studied patients with moderate to severe heart failure, who were enrolled in an international survival study, and compared patterns of drug use between the nine countries that each included >50 patients in the study. The results were analysed to determine whether observed differences between countries could be explained by differences in the patients recruited. 1825 patients were studied (range 81–427 per country). By trial protocol, most patients were treated with angiotensin converting enzyme (ACE) inhibitors (92%) and all with diuretics, but the proportion of patients taking high doses of these drugs was markedly different between countries. Large differences were also observed in the use of digoxin (overall 64%, 39% in the U.K. to 87% in Germany) and antiarrhythmics (overall 25%, with the highest use 44% in France). The use of beta-blockers and calcium antagonists was low (overall 6% and 8%, respectively), but also different between countries. Anticoagulants (overall 43%) were used in many patients in the Netherlands and Switzerland (around 70%), while antiplatelets (overall use 30%) were most often prescribed in Denmark (51%).
Conclusions
Large differences in drug use and dosing for patients with advanced heart failure are observed between (European) countries. None of these differences could be explained by differences in patient characteristics, and whether they are related to factors such as tradition, economic circumstances and national guidelines, etc. is unknown.
Key Words: Heart failure • treatment • international differences
f1 Dr van Veldhuisen is a Clinical Scientific Investigator of the Dutch Heart Foundation.
f2 Correspondence: Dr Dirk J. van Veldhuisen, Department of Cardiology/Thoraxcentre, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.
References
- Clinical Quality Improvement Network Investigators. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. Arch Intern Med. 1996;156:1669–1673
[Abstract/Free Full Text] - Bourassa MG, Gurné O, Bangdiwala SI. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol. 1993;22 (Suppl A):14A–19A
- Pitt B, Nicklas JM. Target doses of ACE inhibitors in heart failure: where should we aim. Eur Heart J. 1998;19:370–371[Web of Science][Medline]
- Packer M, Poole-Wilson P, Armstrong P. Comparative effects of low-dose versus high-dose lisinopril on survival and major events in chronic heart failure: the Assessment of Treatment with Lisinopril and Survival study (ATLAS)(abstract). Eur Heart J. 1998;19 (Abstr Suppl):142
- The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J. 1998;19:481–489
[Abstract/Free Full Text] - Szabó BM, Van Veldhuisen DJ, De Graeff PA, Lie KI. Alterations in the prognosis of chronic heart failure: An overview of the major mortality trials. Cardiovasc Drugs Ther. 1997;11:427–434[CrossRef][Web of Science][Medline]
- Packer M. Do beta-blockers prolong survival in chronic heart failure? A review of the experimental and clinical evidence. Eur Heart J. 1998;19 (Suppl B):B40–B46
- Cleland JGF. Anticoagulant and antiplatelet therapy in heart failure. Curr Opin Cardiol. 1997;12:276–287[Web of Science][Medline]
- Holmes DR, Califf RM, van de Werf F. Difference in countries’ use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO Trial. Lancet. 1997;349:75–78[CrossRef][Web of Science][Medline]
- Hampton JR, Van Veldhuisen DJ, Kleber FX. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet. 1997;349:971–977[CrossRef][Web of Science][Medline]
- Williams JF, Bristow MR, Fowler MB. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 1995;26:1376–1398[Web of Science][Medline]
- The Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J. 1997;18:736–753
[Free Full Text] - The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–533
[Abstract/Free Full Text] - Smith TW. Digoxin in heart failure. N Engl J Med. 1993;329:51–53
[Free Full Text] - Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and on congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet. 1997;350:1417–1424[CrossRef][Web of Science][Medline]
- Massie BM, Cleland JGF, Armstrong PW. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. J Card Fail. 1998;4:3–8[Medline]
- Stevenson WG, Stevenson LW, Middlekauff HR. Improving survival of patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol. 1995;26:1417–1423[Abstract]
- Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37:1022–1036
[Abstract/Free Full Text] - Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol. 1998;31:749–753
[Abstract/Free Full Text] - Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction (SOLVD) Trial. J Am Coll Cardiol. 1998;31:419–425
[Abstract/Free Full Text] - Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation. 1998;97:1231–1233
[Abstract/Free Full Text] - Edep ME, Shah NB, Tateo IM, Massie BM. Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol. 1997;30:518–526[Abstract]
- Reis SE, Holubkov R, Edmundowicz D. Treatment of patients admitted to the hospital with congestive heart failure: speciality-related disparities in practice patterns and outcomes. J Am Coll Cardiol. 1997;30:733–738[Abstract]
- Bart B, Ertl G, Maggioni AP. Contemporary management of patients with left ventricular dysfunction: preliminary results from the study of patients intolerant of converting enzyme inhibitors (SPICE) registry (abstr). Eur Heart J. 1997;18 (Abstr Suppl):402
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. J. van Veldhuisen, A. H. Maass, S. G. Priori, P. Stolt, I. C. van Gelder, K. Dickstein, and K. Swedberg Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008 Eur J Heart Fail, November 1, 2009; (2009) hfp149v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]
|
|
|
|
|
|
H. B. Sturm, F. M. Haaijer-Ruskamp, N. J. Veeger, C. P. Balje-Volkers, K. Swedberg, and W. H. van Gilst The relevance of comorbidities for heart failure treatment in primary care: A European survey Eur J Heart Fail, January 1, 2006; 8(1): 31 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Jaarsma, F. M. Haaijer-Ruskamp, H. Sturm, and D. J. Van Veldhuisen Management of heart failure in The Netherlands Eur J Heart Fail, March 16, 2005; 7(3): 371 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ceia, C. Fonseca, T. Mota, H. Morais, F. Matias, C. Costa, and A. G. Oliveira Aetiology, comorbidity and drug therapy of chronic heart failure in the real world: the EPICA substudy Eur J Heart Fail, October 1, 2004; 6(6): 801 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. De Geest, L. Scheurweghs, I. Reynders, W. Pelemans, W. Droogne, J. Van Cleemput, M. Leventhal, and J. Vanhaecke Differences in psychosocial and behavioral profiles between heart failure patients admitted to cardiology and geriatric wards Eur J Heart Fail, August 1, 2003; 5(4): 557 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kulig, S. Erika, and W. S. Norbert Comparing methodological quality and consistency of international guidelines for the management of patients with chronic heart failure Eur J Heart Fail, June 1, 2003; 5(3): 327 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Pont, W. H. van Gilst, D. J.A. Lok, H. J.A. Kragten, F. M. Haaijer-Ruskamp, and on behalf of the Dutch Working Group on Heart Fail The relevance of heart failure severity for treatment with evidence-based pharmacotherapy in general practice Eur J Heart Fail, March 1, 2003; 5(2): 187 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Kjeldsen, A Norgaard, and M Gheorghiade Myocardial Na,K-ATPase: the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure Cardiovasc Res, September 1, 2002; 55(4): 710 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Zannad Evidence-based drug therapy for chronic heart failure Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D66 - D72. [Abstract] [PDF]
|
|
|
|
 |
|
 R McMullan and B Silke A survey of the dose of ACE inhibitors prescribed by general physicians for patients with heart failure Postgrad. Med. J., December 1, 2001; 77(914): 765 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Komajda, J.B. Bouhour, P. Amouyel, F. Delahaye, E. Vicaut, I. Croce, E. Rougemond, F. Vuittenez, and E. Leutenegger Ambulatory heart failure management in private practice in France Eur J Heart Fail, August 1, 2001; 3(4): 503 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Cosyns and M. Claeys Management of heart failure in Belgium Eur J Heart Fail, August 1, 2001; 3(4): 509 - 512. [Full Text] [PDF]
|
|
|
|
|
|
S. Stewart, L. Blue, S. Capewell, J. D. Horowitz, and J. J. McMurray Poles apart, but are they the same? A comparative study of Australian and Scottish patients with chronic heart failure Eur J Heart Fail, March 1, 2001; 3(2): 249 - 255. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||